An observational study in Acute Heart Failure, sponsored by Sebastian Carballo. Recruiting at 1 site in Switzerland. Open to participants aged 16 Years to 100 Years. Per ClinicalTrials.gov, last updated 2023-05-06.
Sponsored by Sebastian Carballo · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 149 studies in Heart Failure with a site in Switzerland — 21 open to participants now, 32 under way, 1 of them phase 3. Heart Failure · Switzerland.
Among the 149 studies in Heart Failure with a site in Switzerland, this one is the 18th largest by planned enrollment of the 46 observational ones that give a count, is one of 11 that started in 2014, is one of 46 observational ones, reaches primary completion later than 11 of the 31 other live ones, and was the 73rd registered.
6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.
Browse Heart Failure studies →21 of the 149 studies in Heart Failure with a site in Switzerland are open now. Recruiting first, the newest first:
Biotronik SE & Co. KG · Sites in Switzerland, Australia, Austria and 10 more countries
Ages 18+
Fondazione Don Carlo Gnocchi ETS · Sites in Switzerland, Belgium, Italy and 1 more country
Ages 18+
Insel Gruppe AG, University Hospital Bern · Sites in Switzerland, Australia, Bulgaria and 4 more countries
Ages 18+
University Hospital, Basel, Switzerland · Sites in Switzerland, Austria, Bulgaria and 6 more countries
Ages 65+
Bayer · Sites in Switzerland, Austria, Belgium and 14 more countries
Ages 18+
A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →
Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.
This study: 16 Years to 100 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
149 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 10 · Phase 3 25 · Phase 4 17
First in 1983; this study’s year is marked. 11 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,200 is above the median of 200 across 1,987 observational studies indexed under Heart Failure.
Median enrollment 314 across the 100 interventional studies, 589 across the 46 observational. Of the 105 that completed or were terminated, 38 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
82 of 149 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Sebastian Carballo as lead sponsor.
Sebastian Carballo has 1 study filed under Heart Failure — fewer than ten, so there is no comparison to draw.
7 of the studies in Heart Failure with a site in Switzerland that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02444416Sebastian CarballoProspective Registry of Acute Heart Failure | 2026-11 |
| NCT06942221University Hospital, Basel, SwitzerlandDigital Solutions in Heart Therapy (DIGNITY) | 2026-12-31 |
| NCT07319039University Hospital, GenevaBreathlessness Patterns in Patients With Cancer, COPD and Heart Failure: an fMRI Feasibility Study | 2027-03-01 |
| NCT06465498Antonio LeidiInvestigating aCute heArt failuRe Decongestion Guided by Lung UltraSonography | 2027-04-30 |
| NCT07852221Insel Gruppe AG, University Hospital BernPatient Selection and Long-Term Outcomes of Pace & Ablate Strategy in Atrial Fibrillation | 2027-06-30 |
Add all 7 to your calendar (.ics) → With an account.
Among the 149 studies in Heart Failure with a site in Switzerland, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Context:
Heart failure is associated with a high morbidity and mortality rate and represents a significant worldwide public health burden. In European countries, the total amount of the expenses related to heart failure represents 1 to 2% of the total health budget with 75% spent during hospitalizations, making heart failure the most expensive pathology in cardiology. Acute heart failure (AHF) has a poor prognosis despite improvements in therapy. Hospital mortality is 2 to 4% the risk of death or readmission in the six months following hospitalization is high.
Patients hospitalized for heart failure represent a very heterogeneous population in terms of etiologies, clinical presentations and/or co-morbidities. Consequently, this implies variable outcomes in terms of morbidity and mortality, probably due to their different prognostic factors. The precise spectrum of etiologies and prognostic factors of AHF in non selected populations has not been exhaustively studied and only a few predictive models concerning AHF have been validated.
Ischemic heart disease, valvulopathy, arrhythmias, infections, hypertension and lack of therapeutic compliance are often quoted as being the factors triggering heart failure. Some triggering factors (ischemic heart disease, pulmonary infections, acute renal failure) seem to be strongly associated with a poor prognosis in terms of hospital/out-patient mortality and re-hospitalization rate.
The complex relation between heart failure and acute renal failure is defined by the cardio-renal syndrome. Thirty percent of patients hospitalized for AHF will be diagnosed with an acute renal failure at admission or with worsening kidney failure during hospitalization. It seems that heart failure and cardio-renal syndrome are two distinct entities with a different prognosis. The type of acute renal failure (functional, renal or post-renal) in these patients and the prognostic value of these etiologies is still not firmly established.
A thorough determination of the etiologies and prognostic factors of AHF are necessary in order to allow the identification of high-risk patients and the improvement of heart failure management.
Objectives:
Method:
Creation of an observational registry associated with a biobank including patients hospitalized for AHF in the Department of General Internal medicine (SMIG) and in the Departments of Specialties at the University Hospital of Geneva.
Anticipated results:
Patients hospitalized for an acute heart failure
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Prevalence of different clinical presentations of the acute heart failure
Time frame: baseline
Prevalence of the triggers of the acute heart failure
Time frame: baseline
Prognostic factors (including the acute renal failure and worsening renal function) in the acute heart failure
Time frame: baseline
Rehospitalization and early and late mortality
Time frame: 30 days, 90days, 1 year and 2 years
The record gives a start of Dec 2014, a primary completion of Nov 2026 and a completion of Nov 2026. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.